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The fundamental principle that unites addictive drugs appears to be that each enhances synaptic dopamine by
means that dissociate it from normal behavioral control, so that they act to reinforce their own acquisition. This
occurs via the modulation of synaptic mechanisms that can be involved in learning, including enhanced exci-
tation or disinhibition of dopamine neuronactivity, blockadeof dopamine reuptake, and altering the state of the
presynaptic terminal to enhance evoked over basal transmission. Amphetamines offer an exception to such
modulation in that they combine multiple effects to produce nonexocytic stimulation-independent release of
neurotransmitter via reverse transport independent from normal presynaptic function. Questions about the
molecular actions of addictive drugs, prominently including the actions of alcohol and solvents, remain unre-
solved, but their ability to co-opt normal presynaptic functions helps to explain why treatment for addiction
has been challenging.Introduction
Addiction is an unusual disease in that it is not a consequence of
cellular dysfunction: addictive drugs ‘‘hijack’’ normal learning
processes to reinforce their own acquisition. It is further unusual
in being a modern disorder. Roy Wise made the observation in
this journal that ‘‘addiction is quite a recent phenomenon, largely
dependent upon the controlled use of fire (smoking), hypodermic
syringes (intravenous injection), and the cork and bottle (storage
and transportation of alcohol)’’ (Wise, 2000). To more efficient
delivery systems, we add the contributions of modern chemists,
who isolated active components of psychoactive plants (cocaine
and morphine) and invented easily administered drugs (amphet-
amine: AMPH, methamphetamine: METH, toluene, and heroin).
Addictive drugs exhibit a wide range of structures and actions,
but the unifying principle appears to be that they each acutely
enhance striatal dopamine (DA) neurotransmission by means
that dissociate it from normal drive by environmental cues.
Striatal DA levels are normally driven by three major factors: (1)
neuronal firing, which is chiefly modulated by environmental cues
via somatodendritic receptors; (2) reuptake by the DA plasma
membrane uptake transporter (DAT); and (3) the state of the
presynaptic terminal, which controls the number, probability, and
sizeof thequantal events released in response toneuronal activity.
Thus, addictive drugs might in principle act (1) by enhancing
neuronal firing beyond that normally driven by environmental
cues, as do nicotine, opiates, and sedatives; (2) by inhibiting
DA reuptake, as does cocaine; (3) by altering release probability
from the presynaptic terminal, as do nicotine and opiates. Less
predictable from normal synaptic function are the actions of
AMPHs, which (4) release DA via reversal of DAT independent
of synaptic vesicle fusion (Table 1, Figures 1 and 2).
The Concept and Identification of Addictive Drugs
Defining the set of addictive drugs is elusive in part as it depends
on whether society considers them to be destructive. For628 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.example, evidence for clinical opium use extends to 5000 B.C.
in Sumeria, where it was known as ‘‘joy plant’’; among a horde
of opium-related artifacts surviving from the ancient Mediterra-
nean is a goddess from Minoan Crete with a poppy crown asso-
ciated with a vase apparently used for breathing opium vapors
(Kritkikos and Papdaki, 1967). Ancient and medieval Greek and
Arabic pharmacologists who wrote on opium, including Dioscor-
ides, Galen, and Avicenna (Ibn Sina), mention opium’s clinical
use and toxicity but not habit (Tibi, 2006).
Recreational opium smoking was established in China in the
1600s (Tibi, 2006), while opium was mostly eaten in Turkey.
The first western scientific article on opium that I have located
is in 1701 by Dr. John Jones, from the London College of
Physicians (Jones, 1701), who discusses clinical uses, as well
as withdrawal symptoms, including death, after ‘‘lavish use.’’
In the secondwesternmedical article onopium (Awsiter, 1763),
Dr. John Awsiter of the Royal Hospital in Greenwich introduced
the term habit, stating, ‘‘There are many properties in it, if univer-
sally known, that would habituate the use, and make it more in
request with us that the Turks themselves, the result of which
knowledge must prove a general misfortune.’’ He compared
opium’s effects to drunkenness and outlines features of with-
drawal and overdose. He further discussed tolerance of large
doses by those with opium habit. He also wrote of dire conse-
quences for society: ‘‘The lives of the major part of the eastern
countries,where it is somuch requested,would drop in the flower
of their youth, andwhole nations in the space of a century, be de-
populated.’’ He further presaged treating one habit-forming drug
with others by prescribing nervous stimulants, which would have
included ethanol or camphor (Sneader, 1990). It may be that the
contemporary concept of addiction begins here.
The concept of uncontrollable drug habit was popularized by
satirist Thomas De Quincey in Confessions of an English Opium
Eater (1822). The notion of addiction as a mass social scourge
was reinforced in reaction to the British government’s efforts to
Table 1. Acute Effects of Addictive Drugs on DA Neurotransmission
Direct Actions that Alter DA Transmission Relevant Site Resulting Action
Amphetamines DAT substrate, VMAT substrate,
MAO inhibitor, TH activator,
collapse of vesicular pH gradient
DA neuron somatorendritic regions:
DA neuron presynaptic terminals
increased stimulation-independent
DA release by reverse transport
through DAT
Cocaine DAT blocker DA neuron somatorendritic regions:
DA neuron presynaptic terminals
Enhances DA levels associated
with tonic and burst firing
Ethanol unclear, possibly disinhibition unclear Enhanced DA neuron burst firing
Nicotine nAChR agonist presynaptic excitatory and inhibitory
inputs to DA neuron: DA neuron
somatodendritic regions:
DA neuron presynaptic terminals
Disinhibition and enhanced excitation
leads to DA neuron burst firing;
enhanced fraction of DA release
associated with bursts
Opioids m opioid receptor agonists striatal ACh neurons; ventral midbrain
GABAergic neurons and axons; striatal
GABAergic neurons
Disinhibition leads to DA neuron
burst firing; enhanced fraction of
DA release associated with bursts
Sedatives GABAa receptor coactivators
benzodiazepines) / agonists
(barbtuates)
ventral midbrain GABAergic neurons
and likely axons; unclear striatal sites
Disinhibition leads to DA neuron burst
firing; likely enhanced fraction of DA
release associated with bursts
Solvent inhalants unclear, may enhance release probability unclear unclear
DAT, plasma membrane DA uptake transporter; MAO, monoamine oxidase; nAChR, nicotinic acetylcholine receptor; TH, tyrosine hydroxylase.
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and initiating two wars with China to enforce its ability to export it
(1839–1842 and 1856–1860). These actions incited a protest
movement in Britain (Howitt, 1839) that included political and
medical arguments; a medical tract by the Society for the
Suppression of the Opium Trade (Bennett, 1882) includes arti-
cles by doctors who together treated thousands of opium
addicts in China and stresses the dire consequences for society.
Addiction labeled as a disease was further associated with the
adoption of the hypodermic syringe during the American Civil
War, which was said to engender a ‘‘taste’’ for morphine and
opium, as well as the growing temperance movement against
alcohol. To encourage scientific study of addiction, American
medical doctors formed the American Association for the Study
and Cure of Inebriety (AASCI), which published the Journal of
Inebriety from1876 to 1914. An article in the January 8, 1886 issue
of Science on work by Asa Meylert attributed ‘‘many deaths of
patients in hospitals and asylums, and of soldiers on the march,
to thesuddendeprivationofopiumtowhich theyhavebeenaccus-
tomed.’’ Meylert asked for addiction to be treated as ‘‘a disease,
whichmustbe treated asother diseasesare, byappropriate reme-
dies.’’ Themuscarinic antagonist atropinewas already being used
for treatment of opium addiction, but Meylert reported that while it
and cocawere ineffective,marijuana, the glycine receptor antago-
nist strychnine, the muscarinic antagonist henbane, quinine, and
inhalant anesthetic chloroform were indicated.
Cocaine, which followed morphine (Sertuerner, 1817) as an
addictive drug introduced by modern chemists, is the active
agent of the coca leaf (Gaedcke, 1855), which has been culti-
vated for thousands of years and is not considered to be addic-
tive. By 1863, cocaine was being sold to the public, including in
Coca-Cola in 1886; this beverage still continues to contain coca
leaf (Friedman-Rudovsky, 2009).
The still-running argument over cocaine’s addictive qualities
was covered in the April 8, 1887 issue of Science in a discussion
between Brooklyn physicians Dr. J.B. Mattison and Dr. Ham-mond. Mattison presented a long list of patients with cocaine
toxicity and insisted that ‘‘Hammond’s assertion that there is
no danger of cocaine addiction because he himself took half
a dozen doses at intervals of from one to four days’’ was insuffi-
cient evidence against addiction. The June 4, 1887 issue of the
British Medical Journal introduced the term drug ‘‘craze’’ to the
scientific literature in an article on Mattison’s presentation.
In summary, the idea of addiction as disease seems to have
coalesced during the century after Awsiter’s article on opium.
The opiates, cocaine, and ethanol each fulfill Aswiter’s criteria,
as may some AMPHs, some solvents including toluene and
ether, barbiturates, and arguably benzodiazepines. Most individ-
uals who have taken these drugs, however, do not become
addicted. A less classic example is tobacco, which is thought
not to induce tolerance to its rewarding effects. Additional drugs
that may fall into this category include phencyclidine, betel nut,
marijuana, caffeine, g-hydroxybutyrate, and ‘‘hallucinogens’’
including yage, psilocybin, and LSD; these are not so widely
considered to be addictive, but this may change. We do not
review metabolites and combinatorial properties of addictive
drugs, although these are quite interesting; for instance, chloral
hydrate, a component of the Mickey Finn, is metabolized to the
active ethanol metabolite tricloroethanol, while cocaine and
ethanol can react to produce cocaethylene, which may be
more reinforcing than either individual component.
Identification of a Role for DA Neurotransmission
in Addiction
Identification of a ‘‘Reward Pathway’’
The classic behaviorist B.F. Skinner avoided the term ‘‘reward,’’
and there are good reasons for this. Here I use it as the neurosci-
ence literature does, which is similar or identical to positive
reinforcement, and not to imply that DA neurotransmission is
a cause of pleasure. I do not distinguish the substantia nigra
(SN) from ventral tegmental area (VTA) ventral midbrain DA
neurons or the dorsal from the ventral striatum / nucleusNeuron 69, February 24, 2011 ª2011 Elsevier Inc. 629
Figure 1. Network Model of Pathways by
which Acute Exposure to Addictive Drugs
Uncouples Behaviorally Relevant Control
of DA Neurotransmission
Molecular targets that are currently thought to
acutely regulate extracellular dopamine (DA) are
indicated. Neurons that release conventional
excitatory transmitters are in green, inhibitory
transmitters in red, and modulatory transmitters
in blue.
(1) Addictive drugs can alter DA neuronal firing via
excitation or disinhibition.
Nicotine excites DA neurons, directly although
probably for a short duration at somatodendritic
b subunit-containing nicotinic acetylcholine
receptors (nAChR), and probably via more sus-
tained excitation due to activation of a-7 nAChR
on glutamatergic presynaptic terminals on axons
that innervate DA neurons. These excitatory
projections may include inputs from the pedun-
cular pontine tegmentum (PPT), laterodorsal
tegmentum (LDT), subthalamic nucleus (STN),
prefrontal cortex (PFC), and additional nuclei
(see text).
Opiates, nicotine, and benzodiazepines disinhibit
DA neurons by inhibiting ventral midbrain (VM)
GABAergic projection neurons that possess axon
collaterals that modulate DA neuron excitability.
These drugs may provide further disinhibition by
decreasing the drive from external GABAergic
inputs from ventral pallidum (VP), the rostralmedial tegmentum (RMTg), and additional nuclei (see text). The primary targets of these drugs are, respectively,
GABAergic neuron m opiate (mR), b subunit-containing nAChR, and a-1 subunit-containing GABAa receptors. There may be further modulation due to effects
of mR receptors on medium spiny neurons (MSN) that synapse onto VM GABAergic neurons.
(2) Addictive drugs can selectively enhance DA transmission associated with burst firing by presynaptic effects.
The probability of vesicle exocytosis from DA terminals in the striatum is modulated by multiple transmitter systems, prominently including b subunit-containing
nAChR, which is normally activated by tonically active neurons (TAN) that release ACh as a volume or ‘‘social’’ neurotransmitter, i.e., over many synapses; this
tonic ACh functions to enhance the probability of neurotransmitter release. Nicotine levels reached during smoking are thought to desensitize the DA terminal
presynaptic nAChR, but the resulting decreased probability of transmitter release is overcome during high-frequency firing activity, so that nicotine selectively
promotes DA neurotransmission associated with burst firing. A variety of other presynaptic receptors on DA terminals, including GABAa receptors, probably
produce analogous effects, in that the probability of quantal release is comparatively more enhanced with burst firing activity than during tonic activity. The
TAN neurons themselves are modulated by receptors including mR, which inhibits ACh release, and so opiates may proportionally favor burst firing-mediated
DA release in a manner similar to nicotine.
(3) Cocaine increases extracellular DA by inhibiting reuptake by the dopamine uptake transporter (DAT).
(4) The amphetamines combinemultiple cellular effects (Figure 2) including effects on synaptic vesicles that possess the vesicular monoamine transporter (VMAT)
that together enhance cytosolic DA levels and ultimately release the cytosolic DA via reverse transport across the DAT.
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review discusses current controversy on the roles of these
groups (Wise, 2009).
Credit for discovering that striatal DA neurotransmission is
fundamental to drug self-administration is due to two indepen-
dent groups using different means: James Olds and colleagues
in the 1950s and 60s, and the pharmacologists associated with
Aarvid Carlsson, including Nils Hillarp, Annica Dahlstrom, Kjell
Fuxe, and Urban Ungerstedt, who were establishing DA as
a neurotransmitter.
In 1954, Olds and Peter Milner introduced intracranial self-
stimulation by implanting electrodes in the brains of rats and
providing themwith a lever that they could press to apply current
(Olds andMilner, 1954). Soon after, Olds introduced ‘‘intracranial
self-administration,’’ a lever-operated device that would allow
rats to inject drugs via a pipette directly into defined areas of
the brain (Olds and Olds, 1958). The self-stimulation paradigm
provided the initial evidence of how activity in specific brain
regions correlated with the fraction of the time the animals
pressed the lever, while self-administration provided insights
into drug effects at specific brain regions.630 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.Initial experiments demonstrated that rats with electrodes in
the septal area used as much as 92% of the time to bar press,
in contrast to regions where ‘‘animals do everything possible to
avoid stimulation.’’ By 1956, Olds and collaborators found
that stimulation of the hypothalamus was even more rewarding,
eliciting as many as 5000 bar presses per hour. They soon sus-
pected that the efficacy of stimulation of the lateral hypothal-
amus was due to activation of the medial forebrain bundle,
through which DA neurons course from cell bodies in the
midbrain to striatal and cortical targets.
They then attempted to interfere with bar presses by adminis-
tering drugs (Olds et al., 1956). Successful inhibitors of self-
administration included reserpine, which blocks uptake of
catecholamines into synaptic vesicles (Carlsson et al., 1962;
Kirshner, 1962), and chlorpromazine, the antipsychotic, which
Carlsson later showed blocks DA receptors.
By 1958, Olds concluded: ‘‘(i) The cells which mediate primary
rewarding effects are located in a midline system running from
themidbrain through and into the subcortical and cortical groups
of the rhinencephalon. (ii) The cell groups which mediate primary
rewarding effects are different from those whichmediate primary
Figure 2. The Amphetamines Exert Multiple Effects that Together Act to Enhance Extrasynaptic DA Levels by a Release Mechanism that Is
Independent of Synaptic Vesicle Fusion and Inhibits DA Reuptake, while Further Acting to Inhibit Normal Exocytic DA Neurotransmission
The cytosolic enzyme tyrosine hydroxylase (TH) synthesizes the DA precursor, L-DOPA, while cytosolic DA is metabolized by monoamine oxidase (MAO).
The DA uptake transporter (DAT) normally reaccumulates extracellular DA into the cytosol. DA is sequestered from the cytosol via the vesicular monoamine
transporter (VMAT2) to very high levels in synaptic vesicles, using energy from an inward acidic gradient provided by a vesicular ATP-driven proton pump
(not shown).
Amphetamines are DAT substrates and act to favor release via the reverse transport of cytosolic DA. They further act as competitive inhibitors, and thus slowDAT
reuptake.
Once in the cytosol, amphetamines increase cytosolic DA, thereby providing additional substrate for reverse transport, by (1) activating TH; (2) inhibiting MAO;
and (3) redistribution of vesicular DA to the cytosol, probably by VMAT inhibition and/or eliciting DA reverse transport as VMAT2 substrates, and further by
collapsing the synaptic vesicle pH gradient in part due to competition for intravesicular protons.
These effects of amphetamines on synaptic vesicle DA results in a decrease of the quantal size of neurotransmitter released per synaptic vesicle fusion event.
The enhanced extracelluar DA stimulates D2 DA receptors, which further lowers the probability of synaptic vesicle fusion.
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Reviewpunishing effects’’ (Olds, 1958). They validated the role of medial
forebrain projection from themidbrain to the cortical and subcor-
tical areas in these rewarding effects in later lesion studies (Olds
and Olds, 1969).
Also in 1969, Olds and Phillips introduced the concept that
salient stimuli are responsible for the firing of DA neurons by
showing that ventral midbrain neurons fired at a higher
frequency following a tone paired with food presentation,
and lower rates following other tones not paired with a rein-
forcer (Phillips and Olds, 1969). Remarkably, they conclude
with essentially the contemporary understanding of the rules
of DA neuronal firing: ‘‘Thus it was surmised that expectancy
of reward, rather than response to the tones per se, accounted
for the differing rates of firing in midbrain unit activity. These
responses reflect an integration of sensory input with the
internal state, where the response to tones which signified
a reward appropriate to the submotivational state of the
organism was amplified by the degree of that motivation.’’
These insights, along with a posthumous study that outlines
a specific role for VTA neurons (Brauth and Olds, 1977), led
to subsequent explorations to decipher the rules by which
reinforcement control the activity of DA neurons (Schultz,
2011).
By 1976, the year that he died in an accident, Olds wrote
a review on the state of self-stimulation and drive, concluding
that ‘‘noradrenaline neurons might be the reward neurons ad-
dressed to negative drives and DA neurons to positive drives’’
(Olds, 1976). By introducing self-stimulation paradigms using
electrical current and direct drug application, exploiting this to
map the brain regions involved, and characterizing firing modes
by these neurons to reward and stimuli associated with reward,
Olds perhaps provided the strongest contribution to our under-
standing of addiction.Evidence that Addictive Drugs Enhance Striatal DA
Neurotransmission
During this same period, Carlsson’s colleagues developed
histochemical fluorescent techniques showing that DA neurons
originated in the ventral mesencephalon and projected to the
cortex and striatum (Hillarp et al., 1966), in the pathway Olds
had identified. Similarities between the behavioral response to
AMPH and electric self-stimulation of this pathway were
observed, and led Crow and colleagues to suggest that ‘‘the
dopamine-containing system arising from the ventral mesen-
cephalon may function as an activating system involved in the
effects of positive reward on operant behaviour’’ (Anlezark
et al., 1971). A variety of neurochemical experiments to measure
catecholamine release during self-stimulation were conducted,
as well as additional lesioning studies, as reviewed (German
and Bowden, 1974).
Experiments by Wise, Fibiger, Phillips, and others were influ-
ential in convincing the field that DA release was particularly
important for reward, for example by showing that partial DA
receptor blockade increased self-administration of AMPH by
rats, while rats would self-administer direct DA receptor agonists
(Yokel and Wise, 1978). The memorably named DeWit and Wise
(1977) showed that a DA D2 receptor antagonist, but not norepi-
nephrine antagonists, blocked cocaine reinforcement.
An approach that convinced the field at large that DA was
responsible for the actions of addictive drugs was in vivo micro-
dialysis using electrochemical detection. DA release in vivo had
been studied using ‘‘push-pull cannula,’’ but this caused signifi-
cant tissue damage, while voltammetry (Kissinger et al., 1973)
measured catecholamine release and reuptake with extraordi-
nary time resolution (Millar et al., 1985; Rice et al., 1985) and
was effective for studying cocaine and AMPH (Caviness and
Wightman, 1982; Ewing et al., 1983), but could not differentiateNeuron 69, February 24, 2011 ª2011 Elsevier Inc. 631
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norepinephrine and DA. Microdialysis with HPLC electrochemi-
cal detection was pioneered by Ralph Adams and collaborators
(Adams, 1976; Plotsky et al., 1977), who showed that AMPH
released DA, and Ungerstedt’s lab (Ungerstedt and Pycock,
1974), who confirmed this response in the striatum.
Microdialysis studies were extended by Assunta Imperato and
Gaetano di Chiara and colleagues, who demonstrated that
ethanol (Di Chiara and Imperato, 1985), opiates and barbituates
(Di Chiara and Imperato, 1986), and nicotine (Imperato et al.,
1986) increased DA concentrations in striatum, particularly in
the ventral striatum / nAc. Drugs with aversive properties
decreased DA release, and nonabused drugs did not modify
synaptic DA (Di Chiara and Imperato, 1988a).
Most recently, studies in human psychostimulant-naive indi-
viduals have shown that AMPH-mediated DA release as
measured by D2 receptor availability is significantly associated
with effects of the drug reported by the subject as ‘‘happiness’’
and ‘‘energy’’ (Abi-Dargham et al., 2003).
In summary, a role for enhanced striatal DA neurotransmission
in the addictive properties of drugs is supported by:
1. An increase in extracellular DA levels in the striatum
measured following all of the classic addictive drugs
2. An increased level of drug self-administration when DA
receptors are partially antagonized, with cessation at
more complete blockade
3. Inhibition of drug self-administration when catechol-
amines release is decreased by VMAT inhibition or when
DA synthesis is blocked
4. Cessation of self-administration when DA neurons or their
axons are ablated
5. Reports by AMPH naı¨ve individuals providing a correlation
between DA release and self-reported euphoria
Each mechanism of action essentially decouples DA trans-
mitter levels from normal physiological control. From Olds’s
studies, this would be expected to assign the stimuli that were
associated with acquiring these drugs as reinforcements,
providing a conceptual synaptic framework for addiction.Physiological Regulation of Striatal Extracellular DA
Multiple current reviews detail the control of extracellular DA
levels in the striatum (Arbuthnott and Wickens, 2007; Rice and
Cragg, 2008; Sulzer et al., 2010) and new electrochemical
approaches in vivo are more precisely measuring the effects of
midbrain DA neuron firing on striatal DA levels (Sombers et al.,
2009).
Succinctly, midbrain DA neurons fire action potentials in two
patterns. The intrinsic tonic firing pattern exhibits a mean fre-
quency of 4 Hz in the rodent (Grace and Bunney, 1984; San-
ghera et al., 1984) and is maintained in VTA neurons by HCN
channels (Chan et al., 2007) and an after-hyperpolarization
from Ca2+-activated apamin-sensitive K+ channels that delay
a return to threshold (Shepard and Bunney, 1991; Lovejoy
et al., 2001). Superimposed on this activity in vivo are phasic
bursts of two to six action potentials at a frequency of 15 Hz
in rodents. The burst firing is due to the confluence of glutama-632 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.tergic inputs including superior colliculus (Coizet et al., 2006),
the pedunculopointine tegmental nucleus (PPT) (Lokwan et al.,
2000), lateral dorsal tegmental nucleus (Lodge and Grace,
2006), subthalamic nucleus (Iribe et al., 1999; Chatha et al.,
2000), the prefrontal cortex (Tong et al., 1996), and additional
areas (Geisler et al., 2007) and is absent in acute midbrain slices.
Enhanced firing is triggered by conditioned stimuli (Phillips and
Olds, 1969) and sensory (Freeman and Bunney, 1987) stimuli in
rats and by appetitive or conditioned stimuli in monkey (Mireno-
wicz and Schultz, 1996). Downstream from the initial effects on
addictive drugs on dopamine neurotransmission discussed in
this review, relatively long-term, presumably DA-dependent
alterations of plasticity at these excitatory inputs, such as long-
term potentiation, are suspected to play a role in establishing
addiction-related behaviors (Lu¨scher and Malenka, 2011). As
detailed below, nicotine’s actions are in part due to activation
of these synaptic inputs.
Burst firing of VTA DA neurons is depressed by activity of
inhibitory GABAergic inputs, including striatonigral projections
to the SN reticulata that interact with DAergic dendrites of the
SN, the ventral pallidum, the collaterals of ventral midbrain
projection neurons, and a major input from mesopontine rostro-
medial tegmental nucleus (Jhou et al., 2009; Kaufling et al., 2009;
Sesack and Grace, 2010). As detailed below, effects on these
inhibitory synapses play important roles in the actions of opioids,
benzodiazepines, and nicotine.
Modulatory inputs to DA neurons in the ventral midbrain
include cholinergic neurons arriving from the PPT and lateral
dorsal tegmental nucleus, which make synapses onto both DA
and GABAergic neurons (Omelchenko and Sesack, 2006), as
well as serotonin, norepinephrine, orexin, and other peptide
transmitters.
These firing patterns interact with the probability of release
from DA terminals and DAT activity to regulate extracellular
levels. The baseline or ‘‘tonic’’ DA level in the striatum appears
to mostly reflect equilibria due to combined tonic activity and
DAT action. Current estimates of the baseline level in the striatum
are 20 nM (Shou et al., 2006).
The rapid response of carbon fibre electrodes allows
measurement of DA release after a single electrical stimulation.
A single-pulse electrical stimulation of the medial forebrain
bundle (MFB) elicits400 nMDA in anesthetizedmouse striatum
(Gonon, 1997). The burst firing of themidbrain DA neurons cause
sufficient DA release over tonic firing so that DAT is saturated
during the bursts. This increases the duration of the enhanced
striatal DA levels and provides far greater levels of DA per action
potential during bursts than during tonic firing.
The level of DA reached in awake animals, where burst firing or
self-stimulation occurs, appears similar. The average maximum
of spontaneous transients in freely moving rats is 50 nM DA
(Wightman et al., 2007). Intracranial self-stimulation in rats can
elicit DA levels in the nAc > 2 mM (Garris et al., 1999), while
behavioral stimuli elicit 200–500 nM (Robinson et al., 2001).
Due to the dead volume around the electrode, these measure-
ments probably underestimate maximum levels by 2–3 fold
(Sulzer and Pothos, 2000).
Important additional local control in the striatum is determined
by release probability at the DA terminals, which is controlled by
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(Bendor et al., 2010), GABA receptors (Schmitz et al., 2002),
D2 DA receptors (Benoit-Marand et al., 2001; Phillips et al.,
2002; Schmitz et al., 2002), and probably additional presynaptic
receptors, some regulated by complex network properties
(Bamford et al., 2008), which principally act by modulating
presynaptic Ca2+.
Amphetamines
AMPH and its many derivatives might be considered the orchids
of psychoactive drugs. In addition to the herbs khat and
ephedra, the active components of which (cathinone and ephed-
rine) have an AMPH-like structure, nearly 200 substituted
AMPHs have been introduced (Nichols, 1994) including METH,
methylphenidate (Ritalin), and MDMA (ecstacy).
AMPHs encompass the only widely administered class of
drugs that predominantly release neurotransmitter by a nonexo-
cytic mechanism. Multiple effects of AMPH act together to
provide this uniquemechanism of action, and these complexities
provide the reason that its discussion is the longest here; for
more detail refer to a recent review (Sulzer et al., 2005).
AMPH, invented in 1887 (Edeleano, 1887), was bequeathed its
generic name from a contraction of alpha-methyl-phenethyl-
amine. Some notion of its colorful history can be seen from the
1989 Merck Index listing, which lists seventeen trade names,
not including such familiar trade names as Adderall, Benzedrine,
and Dexedrine, or its myriad nicknames. AMPH was introduced
commercially in 1932 as Benzedrine, the free base administered
in inhaler form. In 1936, Smith Kline and French began to sell
Benzedrine without prescription; over 50 million tablets were
sold during the first three years of availability. It is said that the
first widespread use of AMPH spread from campus to campus
following experiments by the Department of Psychology at the
University of Minnesota on alertness in college students (Angrist
and Sudilovsky, 1978). AMPH was made available by prescrip-
tion only on January 1, 1939. AMPH, METH, and methylpheni-
date are still widely prescribed for weight control, narcolepsy,
and attention deficit disorder, with 700,000 Americans currently
taking Adderall, a mixture of S(+) and R()AMPH enantiomers
(Forrester, 2007).
The addictive potential of AMPHwasmentioned in 1937 (Gutt-
mann and Sargeant, 1937) but was a topic of debate (Angrist and
Sudilovsky, 1978) and not fully recognized until the mid-1960s
(Lemere, 1966). AMPH abuse tends to occur in epidemic waves,
as in Japan from 1947 to 1957, when 550,000 Japanese were
using the drug illicitly (Fukui et al., 1994). In Sweden in 1942,
four years after its introduction, an estimated 3%of the country’s
population used AMPH (Rylander, 1972). In the 2007 U.S.
National Survey on Drug Use and Health, the fraction of people
in western states that take METH was 10-fold higher than in
the Northeast. Epidemics are reported for gay and bisexual
men (Urbina and Jones, 2004), and it is associated with a high
incidence of AIDS in HIV+ patients, perhaps in part as its weak
base properties inhibit normal antigen presentation (Tallo´czy
et al., 2008).
The amount of METH or AMPH in the brain probably reaches
5–10 mM following clinical administration (Markov et al., 2008)
but may reach the hundreds of mM following self-administrationin tolerant addicts, who can ingest 3–4 grams over a 6 day period
(Tallo´czy et al., 2008), which may engender greater toxic
response. AMPH and METH showed no differences in terms of
changes in DA release in the dorsal striatum, elimination, or other
pharmacokinetic properties (Melega et al., 1995), and the drugs
are not distinguished in human discrimination studies (Lamb and
Henningfield, 1994). While the occasional statement that METH
is more addictive or potent may be unfounded (Shoblock et al.,
2003), METH was reported to be more effective at increasing
DA levels in the nAc but not dorsal striatum in rats (Goodwin
et al., 2009).
AMPH Effects Both Uptake Transporters and Secretory
Vesicles
Inquiry into pharmacological stimulantmechanismswas initiated
by George Barger and Henry H. Dale (Barger and Dale, 1910),
who found that compounds including b-phenylethylamine, and
the AMPH isomers beta-methylphenethylamine and phenylpro-
pylamine, raise blood pressure. They called such compounds
sympathomimetic. In later work by J.H. Burn and colleagues,
sympathomimetics that caused membrane contraction after
sympathetic postganglionic denervation and were not blocked
by reserpine were labeled directly acting, in contrast to indirectly
acting sympathomimetics that required innervation to produce
contraction and had reserpine-sensitive responses (Burn and
Rand, 1958; Fleckenstein and Burn, 1953). They concluded
that tyramine and AMPH, which were in the second class, ‘‘act
in the normal animal by releasing a noradrenaline-like
substance,’’ the first clear declaration that AMPHs act by
releasing catecholamines.
From the mid-1960s through the ’70s , a variety of studies
showed that AMPH also released catecholamines in the CNS,
including DA (Heikkila et al., 1975), as reviewed (Kuczenski and
Segal, 1994). Ritz and Kuhar pointed out that while self-adminis-
tration of cocaine-like blockers correlated with their binding
efficacy to DAT, AMPH was far more potent than would be ex-
pected from its binding, confirming the findings in the periphery
that release rather than reuptake blockade is most important for
AMPH action (Ritz et al., 1987).
A role for synaptic vesicle DA pools was sometimes doubted
due to contradictory results from reserpine experiments. This
issue was readdressed using transformed cells to express
DAT, the neuronal vesicular monoamine transporter (VMAT2),
or both (Pifl et al., 1995). AMPH released DA only in cells that ex-
pressed DAT, but the release was greater and sustained for cells
that coexpressed VMAT, confirming a role for synaptic vesicle
DA stores. Consistently, cyclic voltammetry studies demon-
strated that knockout mice that do not express DAT did not
exhibit AMPH-mediated DA release (Giros et al., 1996; Jones
et al., 1998), while AMPH-mediated DA release from cultured
VMAT knockout ventral midbrain neurons was depressed by
65% (Fon et al., 1997). As entire neurotransmitter pool can be
measured in the cultures, AMPH was moreover found to rapidly
(30min) increase DA synthesis. Alongwith the drug’s inhibition of
MAO, this provided most of the source for the remaining DA
release from VMAT2 knockout neurons (Larsen et al., 2002).
Thus, there is evidence for cytosolic, vesicular, and newly
synthesized pools that contribute to the DA released by AMPH.Neuron 69, February 24, 2011 ª2011 Elsevier Inc. 633
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cytosolic DA pools both contribute to AMPH action was
provided by cyclic voltammetry studies in striatal brain slice by
Sara Jones and colleagues (Jones et al., 1998). They stimulated
the terminals at regular intervals and perfused AMPH, which
provided a rapid, relatively small amount of baseline, i.e., unsti-
mulated, DA release. Minutes later, the amount of DA released
per electrical pulse decreased while the baseline release
became much larger. Thus, it appeared that most released DA
was initially in synaptic vesicles and had been redistributed to
the cytosol for subsequent reverse transport. A later study
showed that a portion of the decrease in evoked DA release
was due to an inhibitory D2 DA receptor feedback mechanism
(Schmitz et al., 2001) but was still consistent with a role for DA
that previously resided in synaptic vesicles.
Some reports suggested the notion that low concentrations of
AMPH preferentially release catecholamine already resident in
the cytosol, whereas higher concentrations are required to redis-
tribute vesicular catecholamine to the cytosol (Seiden et al.,
1993). If AMPH simply releases cytosolic catecholamine, then
the free catecholamine levels in the cytosol should decrease.
On the other hand, if AMPH redistributes catecholamine from
vesicles to the cytosol, the free cytosolic levels might increase.
Testing these predictions has required a means to measure
cytosolic catecholamines. An initial approach measured free
cytosolic DA in a giant DA neuron in the pond snail Planorbis
corneus (Sulzer et al., 1995); exposure to 10 mMAMPH increased
cytosolic DA, consistent with redistribution of vesicular DA to the
cytosol. When AMPH accumulation by plasmamembrane trans-
porters was skirted by an intracellular injection of 100 mM
AMPH, there was an increase in cytosolic DA within 5 s, indi-
cating that the effects on vesicles are quite rapid.
More recently, Mosharov and colleagues developed intracel-
lular patch electrochemistry tomeasure cytosolic catecholamine
levels in chromaffin cells (Mosharov et al., 2003) and neurons
(Mosharov et al., 2009). In chromaffin cells, they found that
10 mM AMPH induced a 15-fold increase in cytosolic DA within
10–15 min of exposure, indicating a redistribution of vesicular
catecholamines. In contrast, in cell bodies of cultured ventral
midbrain DA neurons, METH decreased cytosolic DA unless
cocaine was added, which apparently blocked reverse transport
(Mosharov et al., 2009). Thus, in chromaffin cell bodies, AMPH
redistributes vesicular DA to the cytosol, but this does not occur
in DA neuronal cell bodies as they lack synaptic vesicles. There
presumably is such redistribution from vesicles to cytosol in
presynaptic terminals, but these are too small to be patched,
and so optical approaches are now being pursued.
AMPH Actions on Synaptic Vesicles
AMPH and METH have long been known to displace catechol-
amines, but not ATP, from suspended chromaffin vesicles
(Carlsson et al., 1963; Shuemann and Philippu, 1962). Uptake
of norepinephrine into isolated small synaptic vesicles was later
shown to be inhibited by AMPH and AMPH analogs (Knepper
et al., 1988).
If AMPH redistributes DA from synaptic vesicles, it should
decrease the amount of transmitter released per secretory
vesicle fusion event, i.e., ‘‘the quantal size.’’ This became test-634 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.able with the development of carbon fiber electrodes capable
of recording quantal exocytosis by amperometry (Wightman
et al., 1991). Using this technology, AMPH provided the first
instance of a manipulation that affected the quantal size of cate-
cholamine release, as amperometric recordings in PC12 cells, an
adrenal chromaffin cell-derived cell line, demonstrated that
10 mM of AMPH for 10 min decreased quantal size by 50%
(Sulzer et al., 1995). Decreased quantal size by AMPH and other
weak bases was later confirmed in chromaffin cells (Mundorf
et al., 1999) and the giant DA neuron of freshwater snail where
Ewing and colleagues demonstrated the existence of two
classes of DA vesicles differentially depleted by AMPH (Ander-
son et al., 1998).
There are at least two nonexclusive hypotheses that may
explain the mechanism by which AMPH redistributes vesicular
monoamines to the cytosol, the weak base hypothesis and
VMAT substrate actions.
The Weak Base Hypothesis
All sympathomimetics are weak bases with amine moieties that
are capable of accepting protons with pKs in the range of 8 to
10 (Sulzer and Rayport, 1990); AMPH is a lipophilic weak base
with a pK of 9.9 and is thus protonated in acidic organelles
including catecholamine vesicles (Sulzer and Rayport, 1990);
once charged, it is less membrane permeable and accumulates
in the acidic structure.
The acidic pH gradient in secretory vesicles provides the
energy to accumulate transmitter against its concentration
gradient (Johnson, 1988). Secretory vesicles are acidic; chro-
maffin vesicles, which are the best characterized, maintain a
pH of 5.0–5.7, depending on conditions (Johnson, 1988; Lee
et al., 2010; Markov et al., 2008; Pothos et al., 2002) that provide
the energy to accumulate monoamine transmitters. The final
catecholamine concentration gradient at equilibrium is impres-
sive; given sufficient synthesis, vesicles can achieve levels
that, if they were free in solution, would be close to a molar (Staal
et al., 2004). As cytosolic catecholamine levels in chromaffin
cells can reach 10 mM (Mosharov et al., 2003), acidification
provides the energy to maintain an accumulation of at least
100,000-fold.
Weak base compounds that are sufficiently membrane
permeable to enter secretory vesicles bind free protons, alka-
linize the existing vesicular acidic pH gradient, and thus
decrease the energy that drives accumulation of neurotrans-
mitter. The alkalinization of vesicle interiors by AMPHwas initially
demonstrated on isolated chromaffin vesicles and in organelles
of cultured midbrain DA neurons (Sulzer and Rayport, 1990).
The concentration required for AMPH to collapse 50% of the
chromaffin vesicle proton gradient was50 mM for isolated vesi-
cles. The effect of AMPH on chromaffin vesicle pH gradients was
neither stereospecific nor blocked by reserpine, suggesting that
much of its entry into the isolated vesicle preparation was due to
lipophilic diffusion rather than via VMAT1. The relationship
between the proton gradient and vesicular monoamine accumu-
lation is not linear and alkalinization of lumenal pH from pH 5.6
to 5.9, a seemingly unimpressive change, would in theory lead
to a loss of 75% of vesicular transmitter.
The hypothesis of vesicular pH gradient collapse by AMPH
was recently confirmed in cultured chromaffin cells with
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(Lee et al., 2010; Markov et al., 2008). Surprisingly, longer-term
METH (24 hr) can lead to a rebound acidification with an accom-
panying delayed increase in quantal size (Markov et al., 2008);
the mechanism underlying this apparent compensation is
unknown.
Even compounds such as ammonium chloride and chloro-
quine, agents long used to disrupt pH gradients in the laboratory,
release DA from cultured DA neurons (Sulzer et al., 1993) and
intact striatum as measured by microdialysis (Sulzer et al.,
1992) via reverse transport after vesicle alkalinization. To date,
all compounds that collapse vesicular pH gradients, including
the weak bases chloroquine and ammonium chloride (Mundorf
et al., 1999; Pothos et al., 2002), and vesicular chloride channel
blockers and the H+-ATPase inhibitor bafilomycin (Pothos et al.,
2002), lower the number of catecholamine molecules in vesicles
in situ, i.e., decrease quantal size (Sulzer and Pothos, 2000),
presumably by redistribution to the extravesicular milieu after
pH gradient collapse.
There are, however, phenomena that occur at vesicles not
explained by this action. First, there is no straightforward
relationship between effects on pH gradients and monoamine
accumulation, which appears mostly to be due to differential
VMAT binding (Reith and Coffey, 1994). Second, the effect of
pH gradient collapse on monoamine release from isolated vesi-
cles is comparatively less efficient than that on monoamine
uptake (Sulzer and Rayport, 1990); this contrasts with findings
of more effective AMPH-mediated release than uptake blockade
at plasma membrane transporters. This could be due to intrave-
sicular binding sites, such as chromogranins that bind catechol-
amines and decrease the genuine free concentration of
transmitter in vesicles.
Several studies have tested the weak base hypothesis by
comparing effects on vesicular pH and catecholamine redistri-
bution. In isolated synaptic vesicles from whole rat brain, 3 mM
AMPH depleted at least 70% of previously accumulated labeled
DA but only collapsed the proton gradient by 12% (Floor and
Meng, 1996), although the level of alkalinization from higher
levels of AMPH (100 mM) appeared to correlate with release.
In chromaffin granule ghosts, AMPH inhibited DA uptake more
effectively than expected from its collapse of pH (Reith and
Coffey, 1994). Another indication that alkalinization may not be
sufficient to fully explain redistribution of vesicular DA is that
bafilomycin, a proton pump inhibitor that is not a VMAT
substrate, decreased the pH gradient 2-fold more than AMPH
(Floor and Meng, 1996) but released DA at only half the rate.
Perhaps most damning to the completeness of the weak base
action for explaining effects at vesicles is that the (S+)-AMPH
stereoisomer is several-fold more effective at blocking uptake
than the (R)-isomer (Peter et al., 1994). In addition to the lack
of a simple relationship between pH gradients and uptake
blockade in isolated vesicles as above, these experiments
endorse a role for VMAT competition, as the (S+)-isomer exhibits
preferential binding to the transporter (Erickson et al., 1996;
Peter et al., 1994).
VMAT Substrate Actions
The vesicular monoamine transporters that harness the energy
from vesicle acidification to accumulate catecholamines, hista-mine, and serotonin were initially cloned from PC12 cells (Liu
et al., 1992) and later termed the vesicular monoamine trans-
porter 1 (VMAT1). The closely related gene expressed preferen-
tially in the CNS is now known as VMAT2 (Erickson et al., 1992).
AMPH and MDMA exhibited 10- to 20-fold-higher affinity for
VMAT2 than VMAT1 (Erickson et al., 1996). VMAT2 preferentially
binds the S(+)-isomer (Gonzalez et al., 1994; Peter et al., 1994;
Reith and Coffey, 1994).
It has not been straightforward to prove that AMPH is a
transported substrate of VMAT (Schuldiner et al., 1993). While
uptake blockade would not itself deplete vesicular transmitter,
there is an ongoing leak of vesicular transmitter, particularly
with synaptic vesicles (Floor et al., 1995; Pothos et al., 2000;
Schonn et al., 2003), even in the presence of the uptake inhibitor,
reserpine. Moreover, as a substrate, AMPH could facilitate
exchange diffusion across VMAT (Partilla et al., 2006) or cause
protons to be released from the lumen via VMAT. The combina-
tion of these effects would increase cytosolic monoamines
providing that AMPH in binding VMAT does not block reverse
transport. Such blockade appears unlikely given a leak of
vesicular transmitter with reserpine, which binds strongly to the
cytosolic face of the transporter, although the mechanism by
which this occurs remains unclear.
AMPH Actions at Plasma Membrane Transporters
The first identification of a specific transmitter uptake system
was by Barbara Hughes and Bernard Brodie, who examined
serotonin and catecholamine uptake in guinea pig blood plate-
lets (Hughes and Brodie, 1959; Hughes et al., 1958). Dengler
and collaborators first demonstrated CNS uptake of catechol-
amines (Dengler et al., 1961). Further insights were provided by
Brodie’s lab technician, Julius Axelrod, who received a PhD after
twenty-one years of work in the Brodie lab (Axelrod, 2003) and
then the 1970 Nobel Prize, in part for that work.
In a reformulation of Burn and Rand’s earlier categories of
sympathomimetics, Axelrod divided drugs that elevated norepi-
nephrine levels in the blood into compounds that (1) prevent
norepinephrine uptake or (2) release norepinephrine (Axelrod
et al., 1961). The tricyclic antidepressants imipramine and chlor-
opromazine were labeled uptake blockers, while reserpine,
AMPH, and tyramine were considered releasers. Axelrod con-
firmed Burn and Rand’s prior hypothesis that AMPH releases
catecholamine and eventually showed that AMPH blocked
both uptake and release of labeled norepinephrine in brain (Ax-
elrod, 1971), underlining the theme that both effects at the trans-
porter may be important.
Plasma membrane and vesicular neurotransmitter trans-
porters utilize electrochemical energy derived from ion gradients
and the transmembrane electrical potential. In principle, concen-
trative transporters must possess at least one conformation that
prevents substrates from simply diffusing down their concentra-
tion gradient, a property often labeled a gating mechanism.
Literature on the traversal of a substrate between internal and
external faces often invokes an alternating access model (Jar-
detzky, 1966), meaning that binding sites for substrates and
cosubstrates are alternately exposed to extracellular and
cytoplasmic environments via conformational changes in the
transporter.Neuron 69, February 24, 2011 ª2011 Elsevier Inc. 635
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ion gradient that would presumably act as a coupled cosub-
strate, principally Na+ (Iversen, 1963), to drive accumulation of
transmitter against a concentration gradient. In striatal synapto-
somes, DA accumulation against a concentration gradient
required the cotransport of 2 Na+ and 1 Cl ions (Krueger,
1990), resulting in net import of two cations per transport cycle,
and these values are nowwidely assumed under ‘‘physiological’’
conditions for DAT although they remains controversial (Pifl and
Singer, 1999). The electrical gradient (i.e., membrane potential)
also contributes to the driving force for substrate uptake. A
variety of studies in the 1970s examined effects of AMPH stereo-
isomers on plasma membrane uptake transport of tritiated cate-
cholamines by synaptosomes and most (Moore, 1978) found the
S(+)-isomer more potent at blocking DA uptake by DAT.
A clear demonstration of genuine AMPH uptake in neuronal-
like cells waited until 1984 (Bo¨nisch, 1984), mostly due to
background lipophilic uptake. The first convincing data that
confirmed AMPH as a transporter substrate in neurons used
low concentrations (5 nM) of radiolabeled AMPH and striatal
synaptosomes (Zaczek et al., 1991a). They showed that AMPH
accumulation was saturable, ouabain sensitive, and temperature
dependent, consistent with active transport. The DAT blockers
GBR12909, methylphenidate, and cocaine, as well as METH,
were potent inhibitors of AMPH accumulation. Interestingly, the
lab’s accompanying study showed evidence that the AMPH
once accumulated into the cytoplasm may not be free but rather
bound to small soluble acidic peptides in the cytosol (Zaczek
et al., 1991b).
Transfection of DAT into cells with whole-cell electrophysio-
logical recordings of the cotransported currents have confirmed
that AMPH is a substrate for DAT. Blockers such as cocaine in-
hibited inward currents due to Na+ cotransport, while AMPH
activated them (Sonders et al., 1997). This approach thus clearly
identified AMPH as a substrate as it activates cotransport. It
appears that AMPH binds even in the absence of extracellular
Na+ in contrast with cocaine, for which Na+ (or Li+ substituted
for Na+) appears to be required for binding (Reith et al., 1980;
Sonders et al., 1997; Wang et al., 2003).
The extent of contributions of both reverse transport and
uptake blockade to AMPH action in striatum was estimated
using rapid electrochemical recordings in brain striatal slice
preparations and a ‘‘random walk/finite difference’’ analysis
that incorporated Michaelis-Menten kinetics. The results
showed that AMPH’s effect on DA overflow was due to both
reverse transport primarily but with an additional important
contribution from reuptake inhibition (Schmitz et al., 2001).
The most prominent model used to explain how AMPH
induces DA release at plasma membrane uptake transporters
is the facilitated exchange diffusion model based on concepts
introduced by Wilfred Stein and colleagues to describe glucose
transport (Stein, 1967). The model relies on a binding site for
substrate that can crisscross the plasma membrane. To accu-
mulate cellular glucose, the binding sitewould take up amolecule
of glucose extracellularly and then translocate the molecule
across the membrane to release the glucose in the cytosol.
Reverse transport would occur when the binding site faces the
cytosol after release of the substrate, where it could bind another636 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.molecule of cytosolic glucose and later release it extracellularly
after its retransversal to the external site. An important aspect
of this model is that the traversal of the binding site is driven
by the substrate; thus, there would be a limit of no more than
onemolecule of glucose released from the cell for eachmolecule
taken up. In Stein’s classical formulation, transport in the reverse
direction would be relatively infrequent due to sodium binding to
the binding site, whichwould bemuch greater at the extracellular
face and favor a confirmation that preferentially elicits uptake.
This idea was specifically extended to catecholamine trans-
porters by Brodie, who suggested that Na+, present at higher
levels on the extracellular surface, would favor an outward-
facing orientation (Bogdanski and Brodie, 1969).
In its adaptation to explaining AMPH action (Paton, 1973), the
facilitated exchange diffusion model states that AMPH-induced
DA release results from translocation of AMPH as a substrate of
DAT, thus increasing the probability that the DAT binding sites
face the cytosol. Then DA, which is at higher concentration in
the cytosol, could bind the internalized binding site, thereby
increasing the rate of reverse transport of DA. A molecule of
DA released by reverse transport would follow the uptake of an
AMPH molecule, and in this model’s classical form, there would
be at most one molecule of DA released for each molecule of
AMPH accumulated. Since there is less intracellular sodium to
immobilize the inward face, most of the reverse traversals of
the binding sites would return empty. AMPH, on the other
hand, would work by increasing the rate of outward-to-inward
traversal. Cotransport of Na+ with a substrate could increase
the affinity for substrate for the inward face and favor reverse
transport (Sammet and Graefe, 1979).
One prediction that might specifically test facilitated exchange
diffusion is that for compounds that elicit release via exchange,
those that are better substrates for uptake should also be better
releasers. The first study I amaware of to examine Paton’s theory
of facilitated exchange diffusion as ameans of AMPH action was
by Rutledge and colleagues (Arnold et al., 1977), in which they
showed that the S(+)-AMPH was a more potent releaser of DA
and norepinephrine than its stereoisomer. They wrote that the
temperature dependence and stereospecificity of AMPH-medi-
ated release ‘‘suggest that a carrier-mediated, facilitated diffu-
sion is involved in AMPH-induced transport of norepinephrine
and DA.’’
The prediction that AMPH-like drugs would exhibit a linear
relationship between the efficacy of DA uptake inhibition and
DA release was confirmed for both AMPH optical isomers, as
well as three other sympathomimetics (Fischer and Cho, 1979).
For instance, S(+)-AMPH was about 3-fold more efficacious
than the R() isomer for both uptake and release. They con-
cluded that while AMPH enhances cytoplasmic DA levels by
‘‘stimulation of granular release,’’ i.e., redistribution of vesicular
DA, and by MAO inhibition, there was no release of DA unless
AMPH was taken up the transporter. This interpretation was
confirmed by electrochemical experiments with cocaine and
tyramine (Chen and Justice, 1998). In contrast, Trendelenburg
and collaborators showed a nonlinear relationship between
uptake and release of various AMPH-like compounds (Langeloh
et al., 1987). They did not confirm the predicted straightforward
relationship between uptake and release, but rather that some
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substrates for uptake. Zinc, moreover, stimulates efflux of intra-
cellular [3H]DA despite its concomitant inhibition of uptake
(Scholze et al., 2002). Thus, there are multiple situations that
that defy the prediction that efflux straightforwardly depends
on whether transporter binding sites face inward or outward.
In summary, despite the difficulty in directly proving classical
facilitated exchange diffusion, there is also little reason to state
that it does not occur. There are instances of AMPH-driven
reverse transport that facilitated exchange diffusion cannot
explain, e.g., AMPH injected directly into giant DA neurons
induces DA reverse transport although the AMPH was never
transported by DAT (Sulzer et al., 1995). Similarly, membrano-
philic weak bases that are not DAT substrates, such as chloro-
quine and methylamine, collapse synaptic vesicle pH gradients
and induce reverse transport halted by DAT blockers (Sulzer
et al., 1993), while under some conditions increasing intracellular
Na+ can drive DA efflux even in the absence of extracellular
AMPH (Khoshbouei et al., 2003; Raiteri et al., 1979). Thus, clas-
sical facilitated exchange diffusion is not sufficient to explain all
of the release of catecholamines by AMPH.
Channel-like Transporter Modes
Patch-clamp recordings of cell lines expressing catecholamine
transporters have displayed transient very large events that
may indicate an ion channel-like mode of conduction of cate-
cholamine (Galli et al., 1996, 1998). Such events resemble un-
coupled ion conductances similar to those recorded in classical
ion channels as well as DAT (Sonders et al., 1997). Combining
patch-clamp with amperometric recordings, Aurelio Galli’s lab
demonstrated that the channel-like activity of DAT was associ-
ated with transmitter flux from DA neurons that could occur
through an aqueous transporter pore (Kahlig et al., 2005). The
channel-like events were rare, consisting of 10,000 molecules
released over at most a few milliseconds, about the size of
quantal DA release events during synaptic vesicle fusion (Pothos
et al., 1998). The authors estimated that about 10% of AMPH-
mediated DA released was due to the channel-like events.
More strikingly, extracellular AMPH increased the frequency of
channel-like release events by 8-fold, while extracellular DA
had no effect on the frequency of the channel-like events.
The ability of AMPH, membranophilic weak bases, and ions to
release transmitter even when not taken up by DAT, as well as
the demonstration of AMPH-induced channel-like release
events, indicates that a more detailed explanation of structural
changes that occur during reverse transport is required. An
aspectmay be due to AMPH’s ability to stimulate the cotransport
of ions and the consequent rearrangement of electrochemical
gradients (Khoshbouei et al., 2003; Sitte et al., 1998). The idea
that AMPH’s increase of intracellular Na+ concentration may
be sufficient to stimulate AMPH-induced DAT-mediated DA
efflux (Khoshbouei et al., 2003) has been used to propose that
this action is essential for its stimulation of DA efflux (Pifl et al.,
2004; Pifl and Singer, 1999). This notion may be consistent
with a ‘‘unified’’ model that encompasses roles for both
substrate and ion gradients, as well as channel-like properties
in whichmultiple substrates could be transported without a shut-
tling binding site, as suggested for bacterial transporters
(Abramson et al., 2003; Huang et al., 2003) in a rocker-switchalternating accessmodel, in which tilting of transporter domains
close a ‘‘cavity’’ on the cytoplasmic side (the inward-facing
conformation) to open a new ‘‘cavity’’ on the extracellular side
(the outward-facing conformation) (Huang et al., 2003; Locher
et al., 2003). A putative glutamate transporter (Yernool et al.,
2004) suggested an alternate model in which coordinated
‘‘flipper’’ movements of two sets of two hairpin loops allows
alternating access by occluding the transporter, providing an
‘‘open state’’ on either side of the membrane without an ‘‘open
channel’’ (Kavanaugh, 2004). These models introduce variations
on classical facilitated exchange diffusion, and in that they do not
require a binding site that traverses the membrane, they provide
both for channel-like events and do not require a maximum limit
of a one-for-one molecule exchange of cytosolic substrate for
extracellular AMPH during reverse transport.
Recent data (Khoshbouei et al., 2004) seem consistent with
such a unified model, invoking an asymmetric transporter that
suggests a conformational property of DAT that typically favors
influx over efflux, but with net flux controlled by transmembrane
substrate gradients, and introduces a potential second
messenger system thatmay provide the basis for these observa-
tions. Evidence for an asymmetric conformation of the trans-
porter is that when the first 22 amino acids of the N-terminal
region of DAT were truncated or if serine residues in that region
were mutated to alanine (which cannot be phosphorylated),
AMPH-mediated DA efflux was reduced by 80%. As mutating
the same serine residues to aspartate in order to simulate serine
phosphorylation resulted in normal AMPH-mediated efflux, the
authors suggested that phosphorylation of serines may shift
DAT from a ‘‘reluctant’’ state to a ‘‘willing’’ state that favors
AMPH-induced DA efflux without disturbing normal DA uptake.
DAT features numerous putative phosphorylation sites and
multiple protein kinases have been found to regulate DAT func-
tion (Carvelli et al., 2002; Granas et al., 2003; Loder andMelikian,
2003;Melikian andBuckley, 1999), some probably bymembrane
trafficking and endocytosis. AMPH can increase protein kinase
C (PKC) activity (Giambalvo, 1992), which can stimulate DAT-
mediated release of DA (Giambalvo, 1992). A clue to effects of
DAT phosphorylation may be that Ca2+/calmodulin-dependent
protein kinase-II (CaMKII) has been implicated in the ability of
AMPH to cause DA reverse transport (Fog et al., 2006), possibly
via promoting a linkage to the SNARE protein, syntaxin-1 (Binda
et al., 2008). This action of syntaxin-1 is suggested to potentiate
channel like activity at DAT (Carvelli et al., 2008). A new and inter-
esting model is that AMPH, by enhancing Na+ and Ca2+ influx,
activates PKC and CAMKII, which phosphorylates DAT, favoring
a syntaxn 1 association that stimulates the channel mode of
reverse transport (Robertson et al., 2009).
Thus, there are multiple suggestions for how a combination of
AMPH and its influence on phosphorylation could elicit a DAT
conformation that favors DA efflux. This would also be a nonclas-
sical variant of facilitated exchange diffusion without a require-
ment of a one-for-one exchange of DA and AMPH molecules.
DAT activation by AMPH can under some conditions even
induce sufficient excitatory current to potentiate neuronal firing
(Ingram et al., 2002), which could explain reports of AMPH-
induced neuronal excitation (Shi et al., 2000) and exocytic cate-
cholamine release (Darracqetal., 2001;PierceandKalivas,1997).Neuron 69, February 24, 2011 ª2011 Elsevier Inc. 637
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AMPH is a competitive inhibitor of MAOs, mediators of amine
catabolism on the outer mitochondrial membrane, but it is not
degraded by the enzyme. AMPH shows five-fold or greater
selectivity for MAO A over MAO B, with an affinity for MAO A in
the range of 10 mM with the S(+) enantiomer, (Mantle et al.,
1976; Robinson, 1985), similar to the preference for S
(+)-AMPH by DAT and VMAT. AMPH is thus probably concen-
trated in the cytoplasm to a level that inhibits MAOs. An AMPH
metabolite, 4-OH-AMPH (a-methyl-p-tyramine), is moreover
likely to serve as a competitive inhibitor of MAO A (Cho and Ku-
magai, 1994).
AMPH has long been noted to enhance DA synthesis, and this
provides an important role in its action under some conditions,
e.g., after reserpine treatment. This effect can be so profound
that AMPH released far more DA into the neuronal culture
medium than was present in the entire culture prior to AMPH
exposure (Larsen et al., 2002). In striatal synaptosomes, AMPH
at concentrations up to 15 mM enhanced DA synthesis by as
much as 70% (Fung and Uretsky, 1982; Kuczenski, 1975). The
mechanism by which AMPH enhances TH activity is unknown
but could involve Ca2+-dependent phosphorylation of serine
residues on TH that regulate enzymatic activity (Griffiths and
Marley, 2001).
Summary of Effect on DA Transmission
Together, AMPH possesses a variety of seemingly independent
actions that make it uniquely able to enhance DA release inde-
pendently of vesicle exocytosis—in fact it seems to decrease
exocytic release due to its weak base properties, VMAT
blockade, and activation of D2 receptor feedback inhibition.
The level of DA after AMPH exposure in the striatum probably
reaches 500 nM to 10 mM (Wieczorek and Kruk, 1994) under
conditions where normal evoked DA release is attenuated or
lost (Jones et al., 1998; Schmitz et al., 2001). Thus, AMPH
induces DA release in a manner uncoupled from normal salient
behavior and might be expected to enhance learned behaviors
associated with self-administration.
Cocaine
Cocaine, derived from the Andean Erythoxylon coca and related
species (Gaedcke, 1855), was clearly identified as a sympatho-
mimetic drug that increased blood pressure (Frolich and Loewi,
1910). Surprisingly, however, it blocked the effect of the paradig-
matic sympathomimetic drug, tyramine (Tainter and Chang,
1927), a finding that was sometimes referred to as the cocaine
paradox.
The paradox was solved by Burn and Rand (Burn and Rand,
1958), who showed that ‘‘the action of cocaine may be to arrest
the release of the noradrenaline-like substance from the store.’’
In other words, their study introduced the oft-confirmed finding
that uptake blockers like cocaine also block reverse transport
due to releasers like AMPH and tyramine. The finding that
cocaine blocks AMPH-mediated release was replicated later in
the CNS (Fischer and Cho, 1979; Heikkila et al., 1975).
Axelrod’s group, in a study to identify which psychostimulants
block reuptake and which induce release, reported that cocaine
blocked norepinephrine uptake into the nerves innervating heart,
spleen, and adrenal gland (Whitby et al., 1960). To my knowl-638 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.edge, this study was the first to show that cocaine blocks cate-
cholamine reuptake, now acknowledged to be its primary means
of elevating extracellular catecholamine levels. Evidence for
this includes that self-administration of cocaine-like blockers
correlated with their binding efficacy to DAT (but not with the
DA releaser, AMPH) (Ritz et al., 1987).
A contemporary means to confirm this mechanism of action
has been to examine DAT-deficient mice. These mice demon-
strated as much as 100-fold longer enhanced levels of DA
following electrical stimulation of the striatum (Giros et al.,
1996) and were ‘‘indifferent’’ to cocaine and AMPHwith no effect
on locomotor activity. Surprisingly, however, they could still learn
self-administration (Rocha et al., 1998), apparently as cocaine
would block DA reuptake by serotonin and norepinephrine trans-
porters (Rocha, 2003), implicating a form of compensation in
those lines. A mutant mouse line with a cocaine-insensitive
DAT, however, did not learn cocaine reward (Chen et al.,
2006). Thus, it appears that the addictive qualities of cocaine
are normally dependent on blockade of DAT function.
The DAT blocker nomifensine, often used to model effects
of cocaine, increases the maximal amplitude of striatal DA
following a single pulse from 20 nM to 250 nM and the decay
time constant by 20-fold (Benoit-Marand et al., 2000). Thus, the
effects of cocaine on neurotranmission as a blocker of normal
reuptake ought to rely on evoked DA release, in contrast to
that of AMPH, which inhibits evoked release via decreased
quantal size. A net effect of both is to indirectly activate D2
receptors, which depresses evoked release (Brodie and Dun-
widdie, 1990; Schmitz et al., 2002).
How might cocaine’s blockade of reuptake interact with the
signaling from burst firing evoked by environmental cues versus
the ongoing release due to tonic activity? These questions
have become addressable recently by the introduction of means
to record striatal DA during behavior by Mark Wightman and
Regina Carelli. In these recordings, DA transients, presumably
due to burst firing, can be measured (Wightman et al., 2007).
With cocaine, the DA transients not only reach higher neuro-
transmitter concentrations in the striatum and nAc, which would
be expected from higher levels reached due to reuptake
blockade at the electrode, but also increase in frequency (Heien
et al., 2005). While the means by which the number of transient
release events in enhanced by cocaine is unknown, it appears
to bemediated by a circuit that involves endocannabioids (Cheer
et al., 2007).
A model of cocaine’s effect on reuptake blockade effect
indicates that diffusion will be enhanced so that far more DA
receptors at sites distal from the site of transmitter release will
be activated (Venton et al., 2003). This conclusion, however, is
complicated by the observation that cocaine also increases
steady-state DA (Heien et al., 2005), probably mostly due to
reuptake blockade of DA released during tonic activity.
Summary of Effect on DA Transmission
Present results indicate that cocaine enhances DA transmission
associated with both tonic and phasic activity, which should
disrupt normal signaling by enhancing baseline DA levels and
decoupling the relative contributions of tonic and burst firing-
mediated modes. Its effect on enhancing transients may further
contribute to an association of cue with reward (the same is true
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different consequences than AMPH, and self-administration
may be due to disruption of the relative response to cue, the
enhanced tonic release, or both.
Ethanol
Ethanol is the most widely used addictive drug, imbibed by over
51% of Americans over the age of 12, with about one quarter of
the population participating in binge drinking (SAMHDA, 2009). It
is moreover freely imbibed by other primates (Schwandt et al.,
2010), rodents (Griffin et al., 2007), and songbirds (Fitzgerald
et al., 1990). Voluntary drinking releases DA in humans (Boileau
et al., 2003), with recent human PET imaging showing that the
equivalent of three drinks increased extrasynaptic DA in the
striatum by 138% inmen and 69% in women (Urban et al., 2010).
It is thus startling that we do not know how ethanol enhances
DA transmission. One reason is because there aremany possible
receptor and channel targets for ethanol, as recently reviewed
(Melis et al., 2009; Morikawa and Morrisett, 2010), but none
that clearly show sufficient effect on DA release at levels
achieved by individuals who consume alcohol for its reinforcing
properties.
How Many Are Enough?
Ethanol is typically measured as blood fraction (blood alcohol
content [BAC], in the U.S. in units of g/100 ml written as a
percentage). As there appears to be no blood/brain barrier to
ethanol penetration, the extracellular levels in brain are close to
those in blood (Robinson et al., 2002). A glass of wine (150 ml,
2.6 M ethanol) yields 0.02% BAC (4.8 mM) in blood of nonalco-
holic 68 kg men, with women achieving 34% higher levels
(Frezza et al., 1990). A typical level for legal intoxication is
0.08% BAC (17 mM), stupor occurs at 0.25% (54 mM), blackout
at 0.35% (76 mM), and lethality at 0.4% (87 mM). Effects on DA
transmission related to self-administration for reinforcing prop-
erties should therefore be present at 5–20 mM ethanol, lower
than that often studied experimentally. Note however that alco-
holics develop tolerance and can achieve extraordinary levels,
as high as 1.20% BAC (260 mM) (Brick and Erickson, 2009).
How Does Ethanol Cause DA Release?
It has been suggested that alcohol activates VTA neurons directly
to release DA into nAc. However, some but not all dialysis exper-
iments show that alcohol application into the nAc alone locally
increases DA overflow while application of alcohol into the VTA
does not (Ericson et al., 2003; Yim et al., 1998), suggesting that
effects at the axons may be required. In contrast, studies of
ethanol using cyclic voltammetry in the striatal slice (Budygin
etal., 2001)demonstratedeffectsofethanol onevokedDA release
only at very high (100–200 mM) alcohol levels, which depressed
release. Thus, the relevant brain sites in striatum are still unclear.
Ethanol might increase DA release by direct excitation of DA
neurons. Some studies show an effect of alcohol to excite DA
neurons in the VTA at concentrations of 20–320 mM (Brodie
et al., 1990; Okamoto et al., 2006). This might involve an inhibi-
tion of potassium channels, including those that regulate
after-hyperpolarizations and the rate of burst firing, as well as
sustained K+ currents (Koyama et al., 2007).
Alternatively, ethanol may act via disinhibition of DA neurons,
most likely at GABA receptors. Ethanol effects on GABA aresuspected to play a part in its effects, notably the motor-impair-
ing and anxiolytic responses, in a manner related to the benzodi-
azepines and barbiturates. Recent evidence suggests a possible
role for extrasynaptic GABAa receptors, as a population of extra-
synaptic receptors containing a-4 subunits were found that
provide a steady inhibition of thalamic neurons with sedative
levels (50 mM) ethanol, (Jia et al., 2008). A recent paper showed
that viral knockdown of the a-4 subunit in the nAc shell but not
the core, decreased alcohol drinking and preference in the rat
(Rewal et al., 2009); perhaps the receptors in that area are
more sensitive than those in the thalamus.
Several classes of striatal interneurons exert ‘‘veto’’ power on
the ability of MSN neurons to fire (Tepper et al., 2004), and if
either these or medium spiny neuron collaterals were inhibited,
the net result of ethanol inhibition of GABAergic activity (or
cholinergic) activity via GABAergic disinhibition could underlie
a presynaptic component of enhanced DA release.
A similar pathway mediated by an ethanol-mediated GABA
receptor disinhibition of DA neurons by ethanol could also occur
in the ventral midbrain (Mereu and Gessa, 1985), as found with
opioids and sedatives (see below). It should be noted that, in
contrast, ethanol appears to enhance GABAb currents on
midbrain DA neurons by activating GIRK currents (Federici
et al., 2009), which may reinstate some inhibition. Alternatively,
opiate receptors on GABAergic VTA projection neurons have
been implicated in the action of ethanol (Xiao and Ye, 2008),
perhaps via ethanol-mediated release of b-endorphin, which
would similarly disinhibit DA neurons.
Other hypotheses have been offered for network effects via
cannabinoids, serotoinin, glycine, NMDA channels, nAChR,
and NMDA receptors, but to date none have been shown to
clearly cause enhanced firing of DA neurons at levels of 5–
20 mM ethanol, although the enhancement of burst firing seems
to involve endocannabioids (Cheer et al., 2007). In summary,
while there is good evidence that levels of ethanol achieved
duringmoderate drinking release DA, andwhile there are amulti-
tude of potential targets, the means by which ethanol releases
DA during drinking at nominally rewarding levels remain unclear.
Acetaldehyde Hypothesis
An alternate idea that has been percolating for decades is that
the active agent responsible for DA release is actually a metabo-
lite. One so studied was an endogenous opioid, tetrahydropapa-
veroline, a DA product that is enhanced by ethanol (Goldstein
and Judson, 1971; Walsh et al., 1970).
Another is the alcohol dehydrogenase product, acetaldehyde,
which is volatile and difficult to handle experimentally. Neverthe-
less, Melis and colleagues have found that acetaldehyde in-
creases midbrain DA neuron firing via a decrease of potassium
current and activation of hyperpolarization-activated inward
currents (Melis et al., 2007). Asmice will self-administer acetalde-
hyde as well as ethanol (Melis et al., 2009), it is possible that this
ethanolmetabolite,which ishighly reactiveand thought tounderlie
liver toxicity in alcoholism, may be responsible for DA release. If
true, it may help explain the mystery of why levels of ethanol that
enhance DA release in vivo are ineffective in the slice: because
there is a slower rate of alcohol metabolism than in the animal.
While there are studies suggesting that tonic firing rates could
be altered by ethanol via effects on potassium channels, currentNeuron 69, February 24, 2011 ª2011 Elsevier Inc. 639
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phasic firing. Using intravenous administration to remove the
effects of cues and cyclic voltammetry in the nAc of awake
rats, Robinson and colleagues discovered small subregions
that reproducibly respond to intravenous ethanol at doses of
0.125 g/kg and higher with increased DA transients associated
with burst firing (Robinson et al., 2009). The authors conclude
that there is regional variability within the NAc at a ‘‘micro’’ level
and that this could be due to groups of DA neurons with overlap-
ping burst activity (Robinson et al., 2009). Alternatively,
increased DA transients could be due to presynaptic effects on
release probability, as with the interneuron modulation sug-
gested above.
If so, ethanol may have very different effects on DA neuro-
transmission than AMPH and cocaine, which are respectively
independent of activity and effective at enhancing signal from
both tonic and phasic cues, in that ethanol may specifically
enhance the signal from salient cues but have little effect on
DA levels associated with tonic activity.
Opioids
The initial modern western scientific monography on opium sug-
gested that it acts at membranes, allowing vessels and nerves to
expand (Jones, 1701). Specific binding sites, the opiate recep-
tors, were identified using radiolabeled opioids somewhat later
(Goldstein et al., 1971) and were found to encompass multiple
subtypes.
Rats will self-administer opioids to the VTA (Bozarth andWise,
1983), and the use of relatively specific ligands indicated that
reinforcement was mostly due to the m opiate receptor (Devine
and Wise, 1994; Di Chiara and Imperato, 1988b). Consistently, m
opiate receptor-deficient mice do not show opioid-mediated
place preference learning but continued to develop place prefer-
ence for cocaine (Contarino et al., 2002).
Most efforts to study opioid effects are on DA neuron firing;
however, mice will self-administer opiates to the nAc as well
(David and Cazala, 2000), and as detailed below, opiates can
provide a frequency-dependent filter of DA transmission via
a circuit including ACh.
Effects on DA Neuron Firing via Disinhibiton
Opioids increase burst firing of VTA DA neurons (Gysling and
Wang, 1983; Nowycky et al., 1978). The second set of authors
suggested that opioids, by acting to depress activity of local
presumably GABAergic neurons in the VTA, or modulating
striatonigral inputs to the SN, would interfere with their recently
characterized inhibition of DA neuron activity (Grace and
Bunney, 1979).
This opioid disinhibition hypothesis was strongly endorsed by
Johnson and North (1992), who used opiate receptor ligands to
confirm that hyperpolarization of the GABA neurons was due to
the m receptor, while agonists of that receptor had no direct
effects on the DA neuron. Importantly, opioids that acted on
the GABA neurons inhibited inhibitory synaptic potentials on
the DA neurons; thus, it appeared that opioids act at m receptors
on local GABA interneurons, hyperpolarizing them and inhibiting
GABA release, and in turn disinhibiting DA neurons.
It should be noted that these effects may not chiefly be GABA
interneurons but rather collaterals of projection neurons (Omel-640 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.chenko and Sesack, 2009; Steffensen et al., 1998) and may
include effects on GABAergic efferent neurons, for instance
from the striatum or laterodorsal tegmentum (Sesack and Grace,
2010; Tepper et al., 1995).
Effects on Release Probability from Terminals via
an ACh Loop
Using cyclic voltammetry in the striatum, Britt and McGehee
found that opioids modulate release probability in a stimulus-
frequency-dependent manner (Britt and McGehee, 2008). In
the striatal slice, opioid m receptors inhibit DA release from single
electrical pulses but have relatively little effect on release from
stimuli meant to emulate burst firing, due to presynaptic facilita-
tion during bursts.
During presynaptic facilitation, the amount of transmitter
released by subsequent stimuli at short intervals is augmented
by a first (priming) stimulus because the increased Ca2+ from
each stimulus has a decay time of a few hundred milliseconds,
and presynaptic Ca2+ levels reach higher levels during the
subsequent stimuli. Presynaptic facilitation in response to burst
stimuli is also observed with nicotine (see below), and ACh is
involved in the effects of opioids on striatal DA release. DA termi-
nals do not have m receptors (Trovero et al., 1990), while striatal
large tonically active neurons (TANs) that release ACh do
express these receptors. Agonists of m opioid decrease the firing
of TAN neurons, which inhibits ACh release, and thus the prob-
ability of synaptic vesicle fusion, as release probability in DA
terminals is enhanced by the ambient ACh activation of presyn-
aptic nAChR receptors (see below). This inhibition is, however,
overcome by presynaptic facilitation of release due to buildup
of higher levels of presynaptic Ca2+ that occur in the DA terminals
during higher-frequency activation of voltage-gated Ca2+ chan-
nels (Zhang and Sulzer, 2004).
As with ethanol and cocaine, the enhancement of burst firing
by opioids appears to involve endocannabinoids, although the
means by which this occurs is unclear (Cheer et al., 2007).
Summary of Effect on DA Transmission
Thus, opioids, by increasing DA release by stimulating burst
firing, while selectively inhibiting release from tonic firing via
actions at the terminals, will enhance the magnitude of phasic
DA neurotransmission relative to baseline, which would be ex-
pected to enhance salience and perhaps learning associated
with reward and addiction.
Sedatives
With all of these drugs, there has been argument about the
potential for addiction, and the controversy about sedatives
continues. Benzodiazepines are said to be mostly taken by
abusers to augment the effects of a ‘‘primary’’ addictive drug
such as methadone (O’Brien, 2005). Currently, between 10%
and 42% of seniors use benzodiazepines prescribed for anxiety
and sleep disorders (Voyer et al., 2010). After several weeks of
administration the drugs are ineffective, and it is speculated
that continuing self-administration is due to a ‘‘psychological
dependence’’ that might be differently parsed from addiction.
Barbiturates, introduced in 1903 (Fischer and v Mering, 1903),
were used in epidemics in the 1930s and ’40s, when 14% of
admissions at ten major hospitals were for barbiturate abuse
(Cozanitis, 2004). Since the introduction of benzodiazepines,
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used as anticonvulsants, and due to decreased availability to
patients, there is relatively little current abuse.
Barbiturates are agonists of GABAa receptors, and at high
concentrations (>50 mM) can open the ion channel in the
absence of GABA (D’Hulst et al., 2009). In contrast, benzodiaze-
pines, which bind at the interface of a and g subunits, are ‘‘allo-
steric agonists’’ that enhance the frequency of ion channel
opening when GABA is also bound. Unlike ethanol, which binds
with higher affinity to GABAa receptors that contain the a4
subunit (see above), benzodiazepines preferentially bind and
facilitate current at receptors with the a1 subunit (Pritchett
et al., 1989).
Effects on DA Neuron Firing
Midbrain DA neurons lack a1 subunit isoforms (Okada et al.,
2004) while many GABA neurons express this subunit (Fritschy
and Mohler, 1995). Recently, Lu¨scher and colleagues found
that while the benzodiazepinemidazolam (MDZ) enhanced inhib-
itory currents measured at DA neurons and fewer spikes were
generated, this response was absent in mice that possess
a mutation in the a1 receptor site responsible for binding benzo-
diazepines (Tan et al., 2010). As expected, wild-type GABA
neurons also showed a decrease in firing with MDZ, but this
was absent in the mutant line, while the neurons continued to
show reduced firing in response to morphine. The mutant line
further did not learn to self-administer MDZ. Thus, as above
with opioids, and possibly ethanol, benzodiazepines enhance
DA neuron firing via disinhibition, although they rely on different
means to inhibit GABA neurons, in this case due to preferential
binding to a1 containing receptors.
Phenobarbital has long been known to release DA (Di Chiara
and Imperato, 1986), although to my knowledge no studies
have addressed the neuronal circuitry by which this occurs.
Effects on Release Probability from Terminals
To my knowledge, the effects of barbiturates and benzodiaze-
pines on locally evoked striatal DA neurotransmission have not
been examined directly, although we find that GABAa agonists
and antagonists have profound effects on evoked DA release
(H. Zhang and D.S., unpublished data). In striatal slice experi-
ments using cyclic voltammetry, the GABAa receptor agonist
muscimol (100 mM, 4 min) inhibited evoked DA release, while
the antagonist, GABAzine (10 mM) had no effect, indicating that
tonic GABA in the slice is insufficient to cause ongoing inhibition
of DA release. Whether the effect of musicmol is directly on DA
neuron terminals or exerts its effect via a circuit, as do opioids,
is unknown.
Similar to effects with opioids and nicotine, the inhibition is
significantly greater for single pulse stimuli than for stimuli that
emulate burst firing; perhaps this is a general property of drugs
that act via disinhibition.
Nicotine
The prevalence of nicotine self-administration is second only to
ethanol, with a third of the population over age 12 using tobacco
products in 2009 (SAMHDA, 2009). It is the largest cause of
death in the US (18.5%), at 25-fold-greater levels than all illicit
drugs combined, and 5-fold greater than deaths related to
alcohol (Mokdad et al., 2004); one must ask whether we are se-lecting the appropriate drugs for prohibition. Nicotine is not re-
ported to induce long-term tolerance to its rewarding effects,
although it produces tolerance to its aversive properties as well
as receptor desensitization, and so may not quite fulfill the Aw-
siter-derived criteria for drugs of addiction in comparison to
the others discussed.
Nicotine’s mechanism of enhancing DA release is to date
unique for addictive drugs in that it seems to mostly be due to
enhancing excitatory input to DA neurons via presynaptic
activation; however, there is additionally evidence for disinhibi-
tion analogous to effects of opioids and sedatives, a direct
effect on DA cell bodies, and altered filtering due to presynaptic
receptors on DA terminals. These relatively complex actions
have been recently reviewed (Dani and Bertrand, 2007; Mao
and McGehee, 2010; Placzek et al., 2009).
The pharmacologically relevant level of nicotine and the
composition of nAChR at particular sites is important due to
different kinetics of activation, desensitization, resensitization,
and upregulation. Maximal brain free nicotine concentration is
estimated as 240 nM per cigarette, which requires 2–3 min,
declining to 25 nM overnight (Rose et al., 2010).
a7 receptors are homomeric pentamers that are highly perme-
able to Ca2+, exhibit a relatively low affinity for nicotine, and are
thought to not desensitize during smoking. a4b2 pentamers have
high- (1.6 mMACh) and low-affinity (62 mMACh) states, with pro-
longed nicotine increasing the high-affinity contribution and also
desensitizing these receptors at reinforcement-related nicotine
levels (Dani and Bertrand, 2007).
Effects on DA Neuron Firing
Identification of the precise nicotinic receptors on midbrain DA
neurons relies on pharmacological tools and remains incom-
plete. The receptors are expressed on both VTA and SN DA
neurons (Nashmi et al., 2007) and include a7 homomers and
a4 and a6 subunits associated with b2. While these receive
a relatively low direct excitation from ACh, as glutamate antago-
nists block all spontaneous excitation in VTA neurons (Mao and
McGehee, 2010), nicotine, however, can directly increase firing
of VTA neurons (Schilstro¨m et al., 2003) via b2 receptors (Pic-
ciotto et al., 1998), which desensitize after a few minutes. This
led John Dani and collaborators to suggest that desensitization
of the receptors is ‘‘a cellular basis for reports that the first ciga-
rette of the day is the most pleasurable’’ (Pidoplichko et al.,
1997).
AChR desensitization on additional neurons also plays key
roles. Nicotinic receptors on VTA GABAergic neurons are mostly
a4b2, although there are apparently some a7 currents. Self-
administered levels of nicotine first activate and then desensitize
these receptors, leading to disinhibition of DA neurons (Man-
svelder et al., 2002), similar to the effects of opioids and seda-
tives discussed above.
More particular to nicotine, however, is the role played at glu-
tamatergic inputs to the ventral midbrain DA neurons, which
have presynaptic a-7 receptors that do not desensitize during
smoking. These presynaptic receptors provide Ca2+ entry and
thus enhance glutamate release. Therefore, while the GABA
receptors rapidly disinhbit DA neurons, the presynaptic inputs
increase activity, leading to enhanced burst firing. An additional
factor, that may apply to other addictive drugs (Lu¨scher andNeuron 69, February 24, 2011 ª2011 Elsevier Inc. 641
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rapidly that it may occur even while an individual is smoking
a cigarette (in contrast to for example administraton of cocaine
or opioids), leading to even more burst firing and associated
DA release (Mansvelder et al., 2003).
Effects on Release Probability at DA Terminals
Nicotine perfused directly into NAc also enhances local DA
release, presumably by a presynaptic action on the DA terminals
in this region. Normal cholinergic release in the striatum is due to
TANs that are small in number (1% of striatal neurons) but
probably interact with all striatal neurons (Zhou et al., 2001).
This tonic release activates presynaptic nicotinic andM5musca-
rinic receptors on DA neurons, which help to maintain DA
neurons in a state of higher release probability (Bendor et al.,
2010; Zhou et al., 2001).
The presynaptic nicotinic receptors on DA terminals possess
b2 subunits (Salminen et al., 2004; Zhou et al., 2001) that desen-
sitize rapidly with nicotine. As normal tonic ACh release provides
nAChR activation that maintain DA terminals in a state of higher
release probability, nAChR antagonists inhibit release. However,
as with the DA cell bodies, nicotine desensitizes the receptors,
providing the odd phenomenon that both nicotinic agonists
and antagonists inhibit evoked DA release following a single
stimulus. This inhibition, via either antagonists or desensitization,
is overcome during higher-frequency stimuli meant to emulate
burst firing (Rice and Cragg, 2004; Zhang and Sulzer, 2004), as
the probability of release is enhanced by Ca2+ entry during
presynaptic facilitation (see above).
Summary of Effect on DA Transmission
Nicotine, by enhancing burst firing at DA cell bodies via disinhibi-
tion and presynaptic excitation, while accentuating DA release
from burst firing and filtering release during tonic firing, would be
expected to profoundly affect the magnitude of phasic DA neuro-
transmission relative to baseline, which would enhance the
learned responses to cues associated with self-administration.
Solvents
A particularly ghastly addiction is the use of glue as an inhalant,
a practice that costs a few cents and is routinely performed by
millions of homeless children in Africa, Asia, South America,
and the Middle East. In Sao Paulo, Brazil, for example 77.5%
of homeless children ages 6–17 use solvents (Kozel et al.,
1995). Anecdotally, many of these children do not survive, and
chronic ingestion may lead to renal failure (Saxena and Ul-Haq,
2005) as well as neuropathy. Oddly, in southeast Asia, this
drug is often known as dendrite in Nepal after an adhesivemanu-
facturer (Thapa et al., 2009). While now uncommon, there was
a related epidemic of ether addiction in 19th century Ireland as
a whiskey substitute (Hart, 1890) that reappeared in Brazil in
the 1960s (Kozel et al., 1995).
The most studied active agent in the glues is toluene, which is
thought to be the solvent most preferred by homeless children.
Toluene, cyclohexane, and benzene are each self-administered
by rodents (Bespalov et al., 2003), and additional small organic
compounds in petrol are likely responsible for similar effects.
A microdialysis study in rats demonstrates that toluene
increases DA levels in the nAc (Riegel et al., 2007). While the
means by which it does so are unknown, there is some sugges-642 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.tion that it may be related to enhancing Ca2+ levels, and it may
elicit a direct enhancement of presynaptic DA release, which
would be a unique mechanism to date, or work to exacerbate
excitation in amanner similar to nicotine by enhancing excitatory
drive. The possibility of a direct excitation of DA neurons is sug-
gested in that toluene can increase the number of quantal
release events from PC12 cells, consistent with a role in
enhancing Ca2+ currents (Westerink and Vijverberg, 2002).
Both possibilities are consistent with findings that toluene and
other abused inhalants enhance quantal release of GABA in
the hippocampus by increasing presynaptic Ca2+ release from
intracellular stores (MacIver, 2009).
There are also reports of toluene effects that may cause
enhanced release via actions on NMDA or GABA receptors
(Bale et al., 2005; Beckstead et al., 2000; Cruz et al., 1998), which
could be similar to NMDA activation by phencyclidine (PCP).
Conclusions
There appear to be four major mechanisms by which addictive
drugs work to reinforce self-administration, with some drugs
participating by multiple means. These are (1) increasing DA
neuron firing via increased excitation and/or disinhibition, (2)
enhancing the relative DA transmission associated with burst
firing by inhibiting release associated with tonic firing, (3)
blockade of DAT reuptake, and (4) increasing cytosolic DA levels
while stimulating reverse transport.
It may be that additional direct effects on DA neuron firing or
direct enhancement of release probability occur, as suggested
by initial research with solvent drugs.
As—with the exception of the fourth mechanism—these
mechanisms are required for normal learning in addition to the
‘‘diseased’’ learning associated with addiction, future pharma-
cologists and physiologists will need to be creative to design
effective strategies for drug treatment that go beyond sub-
stituting one drug that exacerbates DA release for another, as
already recommended by the earliest paper on drug habit
(Awsiter, 1763). Improved behavioral approaches to treat addic-
tion are certainly still well worth developing concurrently with
improved understanding of drug actions.
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